Publisher Wolters Kluwer retracted nine papers reporting Chinese organ-transplant research in July 2026, citing unresolved concerns that the underlying organs may have been sourced from executed prisoners rather than consenting donors — a practice that international transplant-ethics bodies have barred from publication for more than a decade. The retractions, from the journals Liver Transplantation, Hepatology, and Transplantation, are the latest entry in a long-running, publisher-by-publisher effort to clean up a body of Chinese transplant literature first flagged as non-compliant in 2019.
This page summarizes what has been reported, attributes each claim to its source, and explains why the episode is relevant to journal editors, research-integrity offices, and institutions that co-author or fund transplant research — independent of any conclusion about the specific papers or authors involved.
What was reported
According to a summary published by the International Coalition to End Transplant Abuse in China (ETAC), an advocacy organization that campaigns against forced organ harvesting and has tracked publisher retractions in this literature for several years, Wolters Kluwer retracted nine papers across Liver Transplantation, Hepatology, and Transplantation in a notice dated July 8, 2026. ETAC reports that the retraction notices cite potential ethical breaches in donor sourcing and that the publisher’s investigation followed Committee on Publication Ethics (COPE) process, including direct correspondence with the papers’ authors before a retraction decision was reached.
What CASRAI has not independently verified: we have not been able to directly access Wolters Kluwer’s own retraction notices for these nine papers, and the identities of the specific papers, authors, and institutions involved are reported by ETAC rather than confirmed here. Readers who need the authoritative record should consult the retraction notices themselves on the journals’ websites, or search the Retraction Watch database, rather than relying on secondary summaries — including this one.
The background: a 2019 scoping review and a decade of international ethical standards
The current wave of transplant-literature retractions traces back to a 2019 scoping review by Rogers et al., published in BMJ Open, which examined more than 400 English-language papers reporting on organ transplantation in China. Retraction Watch’s own coverage of the review’s aftermath — independently confirmed by CASRAI via direct review of Retraction Watch’s China-retractions archive — describes its central finding: a large share of these papers failed to document verifiable, consent-based donor sourcing, or to disclose whether any transplanted organs originated from executed prisoners.
Using material from executed prisoners without freely given, verifiable consent conflicts with ethical positions held by the World Health Organization, the World Medical Association, and The Transplantation Society, among other bodies, and with the Declaration of Istanbul on Organ Trafficking and Transplant Tourism. Most major transplant and hepatology journals now require authors to attest to donor consent and independent ethics review as a condition of publication, and several publishers — including Elsevier, per reporting cited by ETAC — have adopted formal editorial policies addressing sourcing verification specifically for China-based transplant submissions.
Retraction Watch’s China-retractions coverage notes that progress against the original ~445 flagged papers has been slow: as of its most recent reporting reviewed for this page, only a minority had been retracted years after the review’s publication, with a number of papers still carrying unresolved editorial expressions of concern dating to 2019–2020. Retraction Watch also reported that “thirteen retractions” in a recent year cited the Rogers review directly, and separately covered a much larger action — Wolters Kluwer flagging more than 120 papers tied to a different registry-protocol issue in February 2026 — which is a distinct action from the nine-paper retraction covered on this page and should not be conflated with it.
Why the pace has been slow, and what a retraction actually requires
Retracting a published paper over an undisclosed-sourcing concern is not a unilateral publisher decision. Under COPE’s retraction guidance, editors are expected to investigate specific allegations, seek a response from the authors and often their institutions, and weigh whether the deficiency is a reporting gap (missing consent documentation that may in fact exist) or evidence the research itself violated ethical standards. That correspondence process, repeated across hundreds of papers spread over dozens of journals and multiple publishers, is a significant part of why an original 2019 finding is still producing individual retraction notices in 2026 rather than a single coordinated mass action.
For a detailed walkthrough of how a retraction investigation typically proceeds from initial concern to published notice, see CASRAI’s guide to how long a retraction takes, from notification to correction, and CASRAI’s explainer on how COPE’s guidelines and Core Practices apply to editorial decisions like this one.
Why this matters for research administrators and integrity offices
- Co-authorship and collaboration due diligence. Institutions with active or historical transplant-research collaborations involving Chinese partner institutions have a direct interest in whether any of their own affiliated papers appear in this or related retraction actions, independent of ETAC’s or any other advocacy group’s framing of the broader issue.
- Editorial policy alignment. Journals and editorial boards that have not yet adopted an explicit donor-sourcing attestation requirement for transplant submissions — along the lines of what Elsevier and several transplant-society journals now require — may want to review their own submission checklists against this recurring category of retraction.
- Citation and literature-review hygiene. Researchers and systematic reviewers citing Chinese transplant literature published before ethical-sourcing requirements were standardized should check individual papers against the Retraction Watch database before relying on them, given how much of the original 445-paper set from the 2019 review remains unresolved.
- Institutional recordkeeping. A retraction notice, once issued, should trigger the same recordkeeping and citation-correction workflow research offices apply to any other retraction — see CASRAI’s dictionary entry on retractions and the related retraction statement entry for what a compliant notice should contain.
Frequently asked questions
Who retracted the nine papers, and from which journals?
Publisher Wolters Kluwer, according to reporting summarized by ETAC (the International Coalition to End Transplant Abuse in China). The nine papers were published across three Wolters Kluwer-owned journals: Liver Transplantation, Hepatology, and Transplantation.
What was the stated reason for the retractions?
Per ETAC’s summary of the retraction notices, the stated concern is potential noncompliance with international ethical standards on organ sourcing — specifically, an inability to rule out that transplanted organs originated from executed prisoners without documented, verifiable donor consent. CASRAI has not directly reviewed the underlying notices and recommends consulting them directly for the publisher’s exact wording.
Is this part of a larger pattern, or an isolated action?
It is part of a larger, slow-moving pattern. A 2019 scoping review by Rogers et al. in BMJ Open flagged roughly 445 Chinese transplant papers as non-compliant with international ethical-reporting standards; Retraction Watch’s own tracking shows only a minority have been retracted in the years since, with new retractions, including this one, continuing to arrive individually as publishers work through investigations case by case.
Is this the same as the ~126-paper Wolters Kluwer action reported in February 2026?
No. Reporting on that February 2026 action describes a separate registry-protocol compliance issue affecting a different journal and a much larger set of papers. The nine-paper transplant-ethics retraction covered on this page is a distinct action; the two should not be conflated even though they involve the same publisher.
What should an institution do if it has co-authored transplant research from this period?
Check the specific papers against the publisher’s retraction notices and the Retraction Watch database, follow the institution’s standard retraction-response and research-integrity procedures if a match is found, and consult COPE’s retraction guidance (see CASRAI’s COPE guidelines explainer) for how investigations of this kind are typically expected to proceed.
Sources and further reading
- International Coalition to End Transplant Abuse in China (ETAC), “Wolters Kluwer Retracts Nine Chinese Transplant Papers” — the primary secondary-source summary this page draws on for the specific July 2026 event; ETAC is an advocacy organization opposed to forced organ harvesting, and readers should weigh that framing accordingly.
- Retraction Watch, China-retractions coverage, including reporting on the 2019 Rogers et al. BMJ Open scoping review and the slow pace of subsequent retractions.
- Committee on Publication Ethics (COPE), retraction guidelines and Core Practices — see CASRAI’s own COPE guidelines explainer.
